@misc{MairSchoen, author = {Mair, Johanna and Schoen, Oliver}, title = {New Model for the Pharmaceutical Industry: The Institute for OneWorld Health}, publisher = {IESE Business School}, pages = {33}, abstract = {This case introduces the Institute of OneWorld Health (IOWH), a company dedicated to producing drugs for neglected diseases and the first non-profit pharmaceutical company in the world. Founded in 2000 by Dr Victoria Hale, IOWH took expired and donated patent compounds and developed them through all the stages of clinical testing and approval into drugs to fight the world's most destructive diseases, usually occurring in Third World countries where perceived profitable markets did not yet exist. By 2004 IOWH was at the stage of presenting its first Phase 3 Clinical Trial results for Paromomycin, a drug developed for Visceral Leishmaniasis, which kills as many as 200,000 people each year in India, Bangladesh, Sudan, Brazil, and Nepal. Its next task was to form partnerships with other organisations to manufacture and distribute the drug; the case focuses on Dr Hale's strategy for IOWH going forward, with particular reference to its core competencies and mission. The case encourages students to consider other models with similar aims and to observe how social entrepreneurs such as Dr Hale endeavour to overcome the market failures that exist for basic health care in the world's least developed countries.}, language = {en} } @misc{MairSeelos, author = {Mair, Johanna and Seelos, Christian}, title = {Entropy International: Enabling businesses to make a contribution to sustainable development}, publisher = {IESE Business School}, pages = {21}, abstract = {This case documents the circumstances of managing the growth phase of a start-up company. Entropy International faces the unique challenges and opportunities of social entrepreneurship but also entrepreneurship in general. Founded by a visionary environmental activist in 1996 as an environmental consulting boutique in the United Kingdom, Entropy grew with the emerging needs of large multinational corporations to publicly report on and minimise the environmental and social impacts of their operations. Entropy started out as a two-person consultancy to become the market leader in Europe, selling an integrated environmental, health and safety, quality control and reporting suite. At the time of the case (March 2003), Entropy employed 30 people and expected revenues of 1.6 million pounds for fiscal year 2003.}, language = {en} } @article{MairSeelos, author = {Mair, Johanna and Seelos, Christian}, title = {Sustainable development, sustainable profit}, series = {European Business Forum}, volume = {20}, journal = {European Business Forum}, issn = {1469-6460}, pages = {49 -- 53}, abstract = {Social entrepreneurship can be a powerful tool for corporations to gain entry and build loyalty in developing markets. While economic growth has led to tremendous improvements in personal freedoms and well-being for people in industrialised societies, it has left too many behind. The images of hunger, disease and human misery refuse to disappear from our television screens. How can growth be made more sustainable while at the same time including and benefiting all of society? The paradox is painful: while traditional markets are saturated, billions of people are desperately waiting for companies to cater to their most basic needs and wants. Social entrepreneurs act as change agents that enable the poor to participate in economic life. Entrepreneurs invent business models that can be scaled up and possibly repeated elsewhere: the Grameen Bank model has been replicated all over the world, with huge success. Social entrepreneurship initiatives also constitute local resources that lend themselves to new configurations for novel forms of value creation.}, language = {en} }